Gene · 10666
Papers4,079
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 4,079
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. | Signal Transduct Target Ther | 2025 | 40739089 | PubTator, text mining | PubMed |
| TIGIT Affects CAR NK-cell Effector Function in the Solid Tumor Microenvironment by Modulating Immune Synapse Strength. | Cancer Immunol Res | 2025 | 40736004 | PubTator, text mining | PubMed |
| Biological activity analysis of baicalin nanodrugs: Nanosizing enhances antiviral and anti-inflammatory effects in the treatment of viral pneumonia. | J Pharm Anal | 2025 | 40735029 | PubTator, text mining | PubMed |
| The value of acetylation reader YEATS2 in hepatocellular carcinoma management. | Sci Rep | 2025 | 40731114 | PubTator, text mining | PubMed |
| The Immune Regulatory Functions of CD226 and Its Implications in Immune-Mediated Diseases. | Biomolecules | 2025 | 40723878 | PubTator, text mining | PubMed |
| Early-life human CD8+ T cells exhibit rapid, short-lived effector responses and a unique transcription factor landscape. | Proc Natl Acad Sci U S A | 2025 | 40720649 | PubTator, text mining | PubMed |
Single cell transcriptomic analysis reveals transcriptome differences of different cells between eosinophilic chronic rhinosinusitis with nasal polyps and non-eosinophilic chronic rhinosinusitis with nasal polyps. | PLoS One | 2025 | 40720416 | PubTator, text mining | PubMed |
| Culturing Potential: advances in ex vivo cell culture systems for haematopoietic cell-based regenerative therapies. | Regen Ther | 2025 | 40704043 | PubTator, text mining | PubMed |
| Analyses of peripheral blood NK cells in response to anti-PD-1 therapy in metastatic melanoma patients. | Clin Immunol | 2025 | 40645389 | PubTator, text mining | PubMed |
| iPSC-derived NK cells engineered with CD226 effectively control acute myeloid leukemia. | Exp Hematol Oncol | 2025 | 40624674 | PubTator, text mining | PubMed |
| Elevated soluble CD226 in Takayasu arteritis is useful for differentiation from giant cell arteritis, disease activity assessment, and prognosis prediction. | Medicine (Baltimore) | 2025 | 40550099 | PubTator, text mining | PubMed |
| Human cDC1 enhance cytotoxic function of CD226+ terminally exhausted tumor-infiltrating lymphocytes. | Oncoimmunology | 2025 | 40548437 | PubTator, text mining | PubMed |
| Modulating CD226 and PD-(L)1 pathways improves CMV-specific CD8＋T cell responses in the absence of IL-2. | BMB Rep | 2025 | 40495489 | PubTator, text mining | PubMed |
| A Novel Class of Multi-substituted Diaryl Scaffold Derivatives Inhibit Glioblastoma Progression by Targeting CD155. | Adv Sci (Weinh) | 2025 | 40492418 | PubTator, text mining | PubMed |
| Proteome-wide Mendelian randomization reveals causal associations between plasma proteins and autoimmune thyroid disease. | Sci Rep | 2025 | 40481092 | PubTator, text mining | PubMed |
| Dysregulation of NK cell subsets and phenotypes in COVID-19 patients with comorbid type 2 diabetes. | Clin Sci (Lond) | 2025 | 40471558 | PubTator, text mining | PubMed |
| Impact of immune checkpoint TIGIT on the activation and function of natural killer cells in rheumatoid arthritis patients. | Rheumatology (Oxford) | 2025 | 40465407 | PubTator, text mining | PubMed |
| Correlation of serum Helios, CD226, TIGIT, and Foxp3 with tear film osmotic pressure and dry eye disease in patients with rheumatoid arthritis. | Expert Rev Clin Immunol | 2025 | 40442984 | PubTator, text mining | PubMed |
| NKG2D triggering hampers DNAM-1-mediated signaling in human NK cells. | Front Immunol | 2025 | 40421025 | PubTator, text mining | PubMed |
| Whole-Blood RNA Sequencing Profiling of Patients With Rheumatoid Arthritis Treated With Tofacitinib. | ACR Open Rheumatol | 2025 | 40388487 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10666/papers?page=9